Intervention details: Dogs with lymphoma of varying types (high grade, intermediate grade and low grade) treated with various types of chemotherapy or with prednisolone alone or not treated. Drug doses and duration are not specified. The paper does not state how many dogs were in each of the lymphoma type groups, however there is limited reference to the numbers of dogs in some of the treatment groups. This reflects the focus on survival for the group as a whole rather than in respect of differing treatment regimes.
Study design: Descriptive case series (retrospective)
Outcome studied: Survival in days
Main findings: (relevant to PICO question):
Proportional hazards regression models were used to assess relative risk of death and reported as Hazard ratios (HR) and 95% Confidence
PICO question
In dogs with naturally occurring multicentric B cell lymphoma does treatment with glucocorticoids alone extend survival time when compared to no treatment?
Clinical bottom line
There is weak evidence, due to insufficient studies with untreated control groups, regarding the impact on survival of prednisolone treatment in dogs with multicentric lymphoma.
From the papers identified from the search functions used for the clinical question remission in uncontrolled trials was reported following prednisolone treatment. Details of which can be found in other sections of this paper.
Intervals (CI). The numbers of dogs in each treatment group (chemotherapy including hydroxydaunorubicin, chemotherapy without hydroxydaunorubicin, prednisone alone and no treatment) was not stated for any of the lymphoma types. Based on this study prednisone only showed no advantage over no treatment for dogs with diffuse large centroblastic B cell lymphoma. Across all grades of lymphoma (including some T cell lymphoma dogs) treatment with prednisolone alone increased the risk of death but this increase was only significant when compared to chemotherapy treatment with or without hydroxydaunorubicin and not when compared to the no treatment group.
Limitations:
 The paper is a retrospective study assessing a wide variety of aspects of dogs with histologically confirmed lymphoma. These include classification of cell type (T vs B, mitotic rate and histological types.) It aims to show how survival varies in different treatment regimens and relate this to disease variables.  Cases were recruited through a Veterinary Cancer Society newsletter which could result in loss of patients from veterinary practices without a special interest in cancer treatment which would mean there might be fewer patients in the prednisolone alone or no treatment groups. There was an ongoing study into one treatment regime so this may have been over-represented.  The authors state that the majority of cases came from the USA with a few from Europe and Canada. It is possible that there were variations in treatment choices or histological diagnosis in the cases from Europe however there is no detail provided about the patient numbers involved.  Patients were only included where there was histological confirmation and immunohistochemistry had been performed. Again this might reduce recruitment of patients whose owners were unwilling or unable to perform these tests or where a diagnosis was reached by cytology alone.  Survival time was recorded for all patients and those who remained alive at the time of the study were censored.  As this was a retrospective study, patients were allocated to a particular treatment option based on clinician and owners preference. It is not clear from the paper if cases from particular practices or regions had differing treatment regimes.  There is no reporting of the dose of prednisolone used for the prednisolone alone group or any reporting of the chemotherapy doses used.  Similarly there is no reporting of the numbers of dogs in each treatment group within each category. This reflects the focus on survival for the group as a whole rather than in respect of differing treatment regimes.
Tozon (2006)
Population: Dogs with lymphoma diagnosed by cytology The following dosage regimes were used: Cyclophosphamide 0.3mg/kg/day for 14 days followed by 14 days with no treatment Prednisolone 0.5mg/kg/day for 14 days followed by 7 days without treatment and the schedule then repeated. Chlorambucil 0.2mg/kg/day for 14 days followed by 14 days without treatment and the schedule then repeated. Prednisolone 0.5mg/kg/day for 14 days followed by chlorambucil 0.2mg/kg/day for 14 days and the schedule then repeated.
Study design: Descriptive case series
Outcome studied: Objective -Survival time in weeks
Main findings: (relevant to PICO question):
 6 dogs were given no treatment and mean survival time was 2.5 weeks and disease was extensive in 4 of the dogs. However grade was not mentioned.
 Prednisolone regime was administered to 6 dogs however one of these also received radiotherapy on one occasion. Survival time ranged from 1-7.5 months with a mean of 2.5 months.  Of the 6 dogs and 2 cats that received prednisolone alone only 7 had a temporary reduction in node size.
Limitations:
 The paper is a retrospective study but does not state how patients were identified or if any cases were excluded.  Diagnosis was based on a combination of clinical signs (anorexia, depression, weight loss, anaemia and generalized lymphadenopathy) haematology results and a biopsy of tonsil or popliteal lymph node or bone marrow which would be acceptable assuming all patients had all three criteria assessed. This is not stated in the paper. Furthermore the paper does not state whether dogs had all or some of these symptoms and whether there was a difference in the presentation of dogs and cats.  The paper does not specify the stage/sub stage of the cases reported except to state that the patients that had no treatment had widespread disease.  Mean survival was reported rather than median which given the low numbers of cases is far from ideal. total pages: 12  Paper does not state the survival time of 1 dog that also received radiation therapy and does not state which of the 6 dogs and 2 cats did not get a reduction in node size. There is no indication if location or grade of disease affected this finding.  Regime is not continuous prednisolone as usually recommended in current veterinary practice across the world.
Squire (1973)
Population: Dogs with naturally occurring lymphoma recruited from local veterinary practices.
Sample size: 100 dogs.
Intervention details:
Comparison of 4 different chemotherapeutic treatment schedules :
1. Prednisone 2 mg/kg/day orally for 7 days followed by 1 mg/kg/day thereafter (n=49) 2. Prednisone as above plus cyclophosphamide 5 mg/kg/day orally for 7 days followed by 2.5 mg/kg thereafter (n=34) 3. Vincristine 0.03mg/kg intravenously on day 1 and 8.
Prednisone 1 mg/kg/day orally on days 1 and 8 and days 9-21. Cyclophosphamide 5 mg/kg/day on days 2-7. Regime repeated every 14 days (n=19) 4. Vincristine 0.03mg/kg intravenously on day 1 and 8.
Prednisone 2 mg/kg/day orally on days 1 and 8 followed by 1 mg/kg/day on days 9-21. Cyclophosphamide 5 mg/kg/day on days 15-21. 6-mercaptopurine 5 mg/kg/day on days 15-21. Regime repeated every 30 days (n=25) Dogs that failed to respond to one regime were moved to treatment schedules 2 or 3 and then reported in that group Study design: Non-randomised controlled trial Outcome studied: Mean objective remission duration in days (number of days before regime failed to maintain complete remission (CR) or partial remission (PR) despite drug-induced toxicity. Survival measured as number of days from initial presentation until natural death or euthanasia in terminal disease.
Main findings: (relevant to PICO question):
 This study excluded 18 dogs that died or were euthanased due to advanced disease or an unsatisfactory response to therapy within 14 days of admission from the survival and remission duration data.
 Of the 49 dogs on prednisolone only 20 (41%) achieved complete remission with a mean objective remission time of 53 days (range 14-210 days). Remission induction rapid and usually reached its maximum at 7 days but was often partial within 72h. Partial remissions were not reported. were noted in several animals (number not stated)  9 dogs that failed to achieve remission on prednisolone alone were then treated with schedule 2. 7 of these dogs responded and 2 of these dogs failed to respond to schedule 2.  14 dogs that failed to respond to prednisolone alone or to schedule 2 were treated with schedule 3. Of these 12 achieved complete remission.  Dogs on prednisolone alone were subsequently given chemotherapy if response was unsatisfactory or when refractoriness developed.
Limitations:
 Stage of lymphoma was defined as one of 4 stages (Stage 1 = one lymph node or one anatomic location  Stage 2 = involvement of multiple lymph nodes but limited to one side of the diaphragm  Stage 3 generalized involvement but limited to lymphoid tissue  Stage 4 involvement of any non-lymphoid tissue including viscera or blood or bone marrow nervous system etc. Viscera would normally be classed as stage 4 on the WHO system and the other areas would be as stage 5 on the WHO system Definition of Stage 3 in this study was generalised involvement but limited to lymphoid tissues i.e. lymph nodes, spleen, tonsils, thymus. In the current staging system this would be a group containing Stage 3 and Stage 4 patients.  Only included animals surviving to 14 days. 18 died or were euthanised due to advanced disease or an unsatisfactory response to therapy.  Doesn't state which of the prednisolone alone group went on to get chemotherapy and if this was taken into account in
